Protocol Ledger

NCT03984760 · Phase III · COMPLETED

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Interventional Phase III clinical trial protocol NCT03984760 sponsored by Panion & BF Biotech in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-19 Enrollment: 240 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03984760
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03984760
Protocol FieldVerified Registry Value
NCT IdentifierNCT03984760
Consolidated Lead SponsorPanion & BF Biotech
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment240 participants (ACTUAL)
Registered Start Date2019-06-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03984760
Hospital Research SiteLocationSite Profile
The Second Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Jiangxi Provincial People's HospitalNanchang, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Nanchang UniversityNanchang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI